| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1024242256 |
| P356 | DOI | 10.1186/1742-2094-9-93 |
| P932 | PMC publication ID | 3418196 |
| P698 | PubMed publication ID | 22591862 |
| P5875 | ResearchGate publication ID | 224971206 |
| P2093 | author name string | Achim Berthele | |
| Bernhard Hemmer | |||
| Sabine Cepok | |||
| Thomas Korn | |||
| Johann Sellner | |||
| Martin S Weber | |||
| Markus C Kowarik | |||
| Verena Grummel | |||
| P2860 | cites work | BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth | Q22009942 |
| B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5 | Q24309316 | ||
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
| A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) | Q24677007 | ||
| Functional subsets of memory T cells identified by CCR7 expression | Q28141547 | ||
| A chemokine-driven positive feedback loop organizes lymphoid follicles | Q28142202 | ||
| Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs | Q30637358 | ||
| The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. | Q33611768 | ||
| The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). | Q33654152 | ||
| A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. | Q33731693 | ||
| Chemokines and cell migration in secondary lymphoid organs | Q33807114 | ||
| CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses | Q34726022 | ||
| Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system | Q35091583 | ||
| B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling | Q36791432 | ||
| Lymphoid chemokines in chronic neuroinflammation | Q37186200 | ||
| Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. | Q39808939 | ||
| A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis | Q40185060 | ||
| Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid. | Q42772808 | ||
| Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. | Q43227358 | ||
| Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis | Q47274470 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment | Q48701331 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. | Q53662652 | ||
| CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions | Q60197446 | ||
| Activation-dependent modulation of B lymphocyte migration to chemokines | Q74247915 | ||
| Recent advances in chemokines and chemokine receptors | Q78165392 | ||
| Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inflammation | Q78952383 | ||
| A prospective study on the role of CXCL13 in Lyme neuroborreliosis | Q83663886 | ||
| Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS | Q83780130 | ||
| The chemokine CXCL13 in acute neuroborreliosis | Q84990890 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neuronitis | Q17157137 |
| P304 | page(s) | 93 | |
| P577 | publication date | 2012-05-16 | |
| P1433 | published in | Journal of Neuroinflammation | Q15716679 |
| P1476 | title | CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation | |
| P478 | volume | 9 |
| Q40530656 | Activated GL7+ B cells are maintained within the inflamed CNS in the absence of follicle formation during viral encephalomyelitis. |
| Q48420893 | Altered Expression of CXCL13 and CXCR5 in Intractable Temporal Lobe Epilepsy Patients and Pilocarpine-Induced Epileptic Rats |
| Q99709718 | An immunotherapy effect analysis in Rasmussen encephalitis |
| Q38975695 | Anti-CD20 monoclonal antibodies in multiple sclerosis |
| Q36646146 | Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid. |
| Q89146586 | Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells |
| Q92216912 | B Cell Compartmentalization in Blood and Cerebrospinal Fluid of HIV-Infected Ugandans with Cryptococcal Meningitis |
| Q35937581 | B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination. |
| Q38795434 | B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence |
| Q38050398 | B cells and antibodies in multiple sclerosis pathogenesis and therapy |
| Q38212081 | B cells in MS and NMO: pathogenesis and therapy |
| Q91236273 | B cells in autoimmune and neurodegenerative central nervous system diseases |
| Q27496017 | Biomarkers in Multiple Sclerosis: An Up-to-Date Overview |
| Q35364112 | Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel |
| Q27012726 | Biomarkers of therapeutic response in multiple sclerosis: current status |
| Q33715901 | Borrelia burgdorferi-specific IgA in Lyme Disease |
| Q37239565 | CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study |
| Q47581475 | CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients. |
| Q37009329 | CXCL13 chemokine as a promising biomarker to diagnose neurosyphilis in HIV-negative patients |
| Q90303200 | CXCL13 polymorphism is associated with essential hypertension in Tatars from Russia |
| Q36788638 | CXCL13 promotes isotype-switched B cell accumulation to the central nervous system during viral encephalomyelitis |
| Q92712543 | Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis |
| Q40062596 | Cerebrospinal fluid CXCL13 as a diagnostic marker of neuroborreliosis in children: a retrospective case-control study. |
| Q64108144 | Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study |
| Q46944115 | Cerebrospinal fluid chemokine CXCL13 in the diagnosis of neuroborreliosis in children. |
| Q35850791 | Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome |
| Q89847251 | Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction |
| Q64957483 | Clinical utility of a molecular signature in inflammatory demyelinating disease. |
| Q48371870 | Cognitive impairment in heart failure: A protective role for angiotensin-(1-7). |
| Q24273331 | Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases |
| Q94465903 | Current Progress on Assessing the Prognosis for Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis |
| Q21284848 | Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain |
| Q89531113 | Cytokines and chemokines in cerebrospinal fluid in relation to diagnosis, clinical presentation and recovery in children being evaluated for Lyme neuroborreliosis |
| Q47102132 | Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function |
| Q34628101 | Detection of cerebral spinal fluid-associated chemokines in birth traumatized premature babies by chip-based immunoaffinity CE. |
| Q37252344 | Diagnostic value of cytokines and chemokines in lyme neuroborreliosis |
| Q38121632 | Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. |
| Q35005026 | Effects of an 11-nm DMSA-coated iron nanoparticle on the gene expression profile of two human cell lines, THP-1 and HepG2 |
| Q36476035 | Endogenous adaptation to low oxygen modulates T-cell regulatory pathways in EAE. |
| Q36742625 | Endometrial CXCL13 expression is cycle regulated in humans and aberrantly expressed in humans and Rhesus macaques with endometriosis |
| Q28535303 | Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis |
| Q36919822 | Glial cell activation, recruitment, and survival of B-lineage cells following MCMV brain infection |
| Q34423587 | Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. |
| Q93020385 | Impact of B cells to the pathophysiology of multiple sclerosis |
| Q35568103 | Inflammation in the pathogenesis of lyme neuroborreliosis |
| Q55043186 | Interrelation of Diet, Gut Microbiome, and Autoantibody Production. |
| Q37618443 | Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study. |
| Q44681284 | Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation |
| Q36813361 | Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response |
| Q38808646 | Leptomeningeal Enhancement at 7T in Multiple Sclerosis: Frequency, Morphology, and Relationship to Cortical Volume |
| Q58742136 | Longitudinal Persistence of Meningeal Enhancement on Postcontrast 7T 3D-FLAIR MRI in Multiple Sclerosis |
| Q90398839 | Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections |
| Q22252398 | Lyme disease: A rigorous review of diagnostic criteria and treatment |
| Q40436486 | Neuroborreliosis |
| Q61806258 | Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report |
| Q35739397 | Process of hepatic metastasis from pancreatic cancer: biology with clinical significance |
| Q34059107 | Progression from IgD+ IgM+ to isotype-switched B cells is site specific during coronavirus-induced encephalomyelitis. |
| Q58761139 | Prophylactic Zinc and Therapeutic Selenium Administration Increases the Antioxidant Enzyme Activity in the Rat Temporoparietal Cortex and Improves Memory after a Transient Hypoxia-Ischemia |
| Q41933450 | Protective Humoral Immunity in the CNS Requires Peripheral CD19-Dependent Germinal Center Formation Following Coronavirus Encephalomyelitis. |
| Q33772300 | Regulated Production of CXCL13 within the Central Nervous System |
| Q36366897 | Rituximab combination therapy in relapsing multiple sclerosis |
| Q91235665 | Serum CXCL13 reflects local B-cell mediated inflammatory demyelinating peripheral neuropathy |
| Q36761844 | Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges |
| Q36551188 | Targeting CXCL13 During Neuroinflammation |
| Q28071379 | Tertiary Lymphoid Organs in Central Nervous System Autoimmunity |
| Q34546457 | The A Allele of the Single-Nucleotide Polymorphism rs630923 Creates a Binding Site for MEF2C Resulting in Reduced CXCR5 Promoter Activity in B-Cell Lymphoblastic Cell Lines |
| Q26776542 | The Ins and Outs of B Cells in Multiple Sclerosis |
| Q64244063 | The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders |
| Q38601694 | The Role of BAFF System Molecules in Host Response to Pathogens |
| Q58798273 | The chemokine CXCL13 in cerebrospinal fluid in children with Lyme neuroborreliosis |
| Q38102623 | The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis |
| Q36069567 | The role of chemokine C-C motif ligand 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients |
| Q38092972 | The utility of cerebrospinal fluid analysis in patients with multiple sclerosis |
| Q42002738 | Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice |
| Q49213573 | Treatment strategies for autoimmune encephalitis |
| Q34552711 | Unilateral phrenic nerve lesion in Lyme neuroborreliosis. |
| Q36117017 | Utility of CSF Cytokine/Chemokines as Markers of Active Intrathecal Inflammation: Comparison of Demyelinating, Anti-NMDAR and Enteroviral Encephalitis |
| Q92251928 | Utility of chemokines CCL2, CXCL8, 10 and 13 and interleukin 6 in the pediatric cohort for the recognition of neuroinflammation and in the context of traditional cerebrospinal fluid neuroinflammatory biomarkers |
| Q90479562 | Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis |
| Q89247252 | [CXCL-13 as a biomarker in the diagnostics of neuroborreliosis] |
| Q87558139 | [CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine] |
Search more.